trial
as of 2026-07-01Safety and Tolerability Study of Drug to Treat Schizophrenia
NCTId NCT00044005
at a glance
Phase 2 · Completed
Enrollment 98 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2003-11
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
98 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2002-09
Primary completion
2003-11
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Medical Director, MDStudy Director
Sites
26 total
Birmingham, United StatesCerritos, United StatesGarden Grove, United StatesGlendale, United StatesLa Mesa, United StatesOrange, United StatesSan Diego, United StatesWashington D.C., United StatesMelbourne, United StatesNorth Miami, United StatesTampa, United StatesWinter Park, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
98
Phase
PHASE2
Primary Completion Date
2003-11
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person